1,474
Participants
Start Date
October 6, 2003
Primary Completion Date
June 9, 2009
Study Completion Date
June 9, 2009
Havrix®
2 doses administered intramuscularly
M-M-R®II
1 dose administered subcutaneously
VARIVAX®
1 dose administered subcutaneously
GSK Investigational Site, Brooklyn
GSK Investigational Site, Albany
GSK Investigational Site, Syracuse
GSK Investigational Site, Rochester
GSK Investigational Site, Beaver Falls
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Sellersville
GSK Investigational Site, Rydal
GSK Investigational Site, Norristown
GSK Investigational Site, Baltimore
GSK Investigational Site, Norfolk
GSK Investigational Site, Lumberton
GSK Investigational Site, Sylva
GSK Investigational Site, Marietta
GSK Investigational Site, Jacksonville
GSK Investigational Site, Bristol
GSK Investigational Site, Kingsport
GSK Investigational Site, Kingsport
GSK Investigational Site, Lexington
GSK Investigational Site, Cleveland
GSK Investigational Site, University Heights
GSK Investigational Site, Waukee
GSK Investigational Site, Waterloo
GSK Investigational Site, Marshfield
GSK Investigational Site, Bossier City
GSK Investigational Site, Cabot
GSK Investigational Site, North Little Rock
GSK Investigational Site, Jonesboro
GSK Investigational Site, Tulsa
GSK Investigational Site, Temple
GSK Investigational Site, Austin
GSK Investigational Site, Layton
GSK Investigational Site, South Jordan
GSK Investigational Site, Las Vegas
GSK Investigational Site, Henderson
GSK Investigational Site, Rolling Hills Estates
GSK Investigational Site, Huntington Beach
GSK Investigational Site, Oakland
GSK Investigational Site, Norwich
GSK Investigational Site, Warwick
GSK Investigational Site, San Antonio
Lead Sponsor
GlaxoSmithKline
INDUSTRY